PSY18 COST-EFFECTIVENESS OF TOFACITINIB IN ACTIVE PSORIATIC ARTHRITIS AFTER ANTI-TUMOUR NECROSIS FACTOR (ANTI-TNF) FAILURE OR INTOLERANCE IN SPAIN | Publicación